1-3 of 3
P. Lane
Close
Sort by
Journal Articles

Satisfaction and Convenience of Chelation Therapy in Patients with Sickle Cell Disease (SCD): Comparison between Deferasirox (Exjade ® , ICL670) and Deferoxamine (DFO).

E. Vichinsky, R. Fischer, Z. Pakbaz, O. Onyekwere, J. Porter, P. Swerdlow, T. Coates, P. Lane, B. Files, B.U. Mueller, L. Coïc, G. Forni, L. Abetz, J.F. Baladi, C. Ressayre-Djaffer, I. Gathmann, D. Alberti, P. Marks
Journal: Blood
Blood (2005) 106 (11): 2334.
https://doi.org/10.1182/blood.V106.11.2334.2334
Published: 2005
Journal Articles

A Randomized, Controlled Phase II Trial in Sickle Cell Disease Patients with Chronic Iron Overload Demonstrates That the Once-Daily Oral Iron Chelator Deferasirox (Exjade ® , ICL670) Is Well Tolerated and Reduces Iron Burden.

E. Vichinsky, R. Fischer, E. Fung, O. Onyekwere, J. Porter, P. Swerdlow, T. Coates, P. Lane, B. Files, B. U. Mueller, F. Bernaudin, G. L. Forni, C. Ressayre-Djaffer, I. Gathmann, J. Holland, D. Alberti, P. Marks
Journal: Blood
Blood (2005) 106 (11): 313.
https://doi.org/10.1182/blood.V106.11.313.313
Published: 2005
Journal Articles

A novel CDK inhibitor, CYC202 (R-roscovitine), overcomes the defect in p53-dependent apoptosis in B-CLL by down-regulation of genes involved in transcription regulation and survival

Azra J. Alvi, Belinda Austen, Victoria J. Weston, Christopher Fegan, David MacCallum, Athos Gianella-Borradori, David P. Lane, Mike Hubank, Judith E. Powell, Wenbin Wei, A. Malcolm R. Taylor, Paul A. H. Moss, Tatjana Stankovic
Journal: Blood
Blood (2005) 105 (11): 4484–4491.
https://doi.org/10.1182/blood-2004-07-2713
Published: 2005